{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:56:45Z","timestamp":1784170605586,"version":"3.55.0"},"reference-count":51,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T00:00:00Z","timestamp":1527033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Forty percent of Hodgkin lymphoma (<jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content>) patients are older than 50\u00a0years at diagnosis, a fact which is not commonly recognized. Older patients do significantly worse than younger patients and are rarely included in clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using data from Swedish Cancer and Lymphoma Registries, we estimated relative survival ratios (<jats:styled-content style=\"fixed-case\">RSR<\/jats:styled-content>s) for 7997 <jats:styled-content style=\"fixed-case\">HL<\/jats:styled-content> patients (diagnosed 1973\u20102013; 45% \u226550\u00a0years).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 1\u2010year <jats:styled-content style=\"fixed-case\">RSR<\/jats:styled-content>s (95% confidence interval; <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>) for males aged 45\u201059, 60\u201069, 70\u201080, and 81\u00a0years and over, diagnosed in 2013, were 0.95 (0.91\u20100.97), 0.88 (0.81\u20100.92), 0.74 (0.63\u20100.81), and 0.52 (0.35\u20100.67), respectively. The corresponding 1\u2010year <jats:styled-content style=\"fixed-case\">RSR<\/jats:styled-content>s for females were 0.97 (0.94\u20100.98), 0.91 (0.85\u20100.95), 0.82 (0.73\u20100.88), and 0.66 (0.50\u20100.77). No improvements in 1\u2010year of 5\u2010year relative survival from 2000 to 2013 were observed for patients aged 45\u201059 or 60\u201069 but there were modest improvements for patients aged 70\u00a0years and older. Importantly, we saw no changes in the distribution of disease or patient characteristics between 2000 and 2013.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Elderly patients constitute a large group with clearly unmet medical needs. Our findings motivate a more active approach to including elderly patients in clinical trials. Our study provides a baseline for outcome comparison after the broader introduction of targeted drugs.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13090","type":"journal-article","created":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T16:35:32Z","timestamp":1525451732000},"page":"106-114","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma\u2014A population\u2010based study from Sweden"],"prefix":"10.1111","volume":"101","author":[{"given":"Magnus","family":"Bj\u00f6rkholm","sequence":"first","affiliation":[{"name":"Department of Medicine Division of Hematology Karolinska University Hospital Solna and Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8231-8183","authenticated-orcid":false,"given":"Caroline E.","family":"Weibull","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5806-0573","authenticated-orcid":false,"given":"Sandra","family":"Eloranta","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna Clinical Epidemiology Unit Karolinska Institutet and Karolinska University Hospital Solna  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin E.","family":"Smedby","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna Clinical Epidemiology Unit Karolinska Institutet and Karolinska University Hospital Solna  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Glimelius","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna Clinical Epidemiology Unit Karolinska Institutet and Karolinska University Hospital Solna  Stockholm Sweden"},{"name":"Department of Immunology Genetics and Pathology Clinical and Experimental Oncology Uppsala University and Uppsala Akademiska Hospital  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Dickman","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,23]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-302604"},{"key":"e_1_2_7_3_1","first-page":"1369","article-title":"Hodgkin lymphoma in older patients: an uncommon disease in need of study","volume":"22","author":"Evens AM","year":"2008","journal-title":"Oncology"},{"key":"e_1_2_7_4_1","first-page":"713","volume-title":"Hodgkin\u2019s disease","author":"Guinee VF","year":"1999"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30003"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392104"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e328348c6c1"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.4181"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.104059"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.2714"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2016.05.008"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505949"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.4444"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.1180"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24623"},{"key":"e_1_2_7_16_1","first-page":"13","article-title":"Risk\u2010 and response\u2010adapted strategies for the management of Hodgkin lymphoma","volume":"4","author":"Remer M","year":"2015","journal-title":"Chin Clin Oncol"},{"key":"e_1_2_7_17_1","first-page":"438","article-title":"Hodgkin\u2019s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis","volume":"88","author":"Landgren O","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24184"},{"key":"e_1_2_7_19_1","first-page":"982","article-title":"Hodgkin\u2019s lymphoma in the elderly: a different disease in patients over 60","volume":"21","author":"Klimm B","year":"2007","journal-title":"Oncology"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3289"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2016.05.011"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12582"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/02841860802247664"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22912"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1977.tb01505.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-73-6-881"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089"},{"key":"e_1_2_7_28_1","unstructured":"Regionalt cancercentrum Syd.Nationella kvalitetsregistret f\u00f6r lymfom: Nationell kvalitetsrapport f\u00f6r diagnosperioden 2000\u20102015 Lund: Regionalt cancercentrum Syd;2016[Available from:http:\/\/www.cancercentrum.se\/globalassets\/cancerdiagnoser\/blod-lymfom-myelom\/lymfom\/rapporter\/lymfom2016_sept23.pdf."},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609067582"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059009"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.00030.x"},{"key":"e_1_2_7_32_1","unstructured":"Swedish Lymphoma Study Group.National guidelines for the diagnosis and treatment of Hodgkin lymphoma2016[Available from:http:\/\/www.swedishlymphoma.com\/hodgkinlymfom."},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1980.228"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61940-5"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/028418602321028283"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2006.01677.x"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X1501500112"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28645"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X0900900206"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.3109\/02841861003782017"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-115493"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2014.050"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2016.05.005"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190601126610"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0463.2002.100503.x"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05498-8"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-644336"},{"issue":"1","key":"e_1_2_7_51_1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V130.Suppl_1.733.733","article-title":"Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv\u2010AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study","volume":"130","author":"Evens AM","year":"2017","journal-title":"Blood"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.01.001"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13090","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T02:05:45Z","timestamp":1695434745000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,23]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/ejh.13090"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13090","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,23]]},"assertion":[{"value":"2018-04-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}